Iscalimab is a Monoclonal Antibody owned by Novartis, and is involved in 15 clinical trials, of which 8 were completed, 6 are ongoing, and 1 is planned.
Iscalimab is a Fc-silent anti-CD40 antibody. The drug candidate inhibits the interaction of CD40 ligand binding to CD40 which results in T cell mediated immune responses suppression. The CD40 stimulation results in the T cell priming and T cell-mediated effector functions and also upregulate costimulatory molecules and activate macrophages, NK cells, and endothelia as well as participate in organ-specific autoimmune disease, graft rejection.
The revenue for Iscalimab is expected to reach a total of $998m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Iscalimab NPV Report.
Iscalimab is under development for the treatment of type 1 diabetes mellitus, myasthenia gravis, primary Sjogren's syndrome, lupus nephritis and moderate to severe hidradenitis suppurativa. The drug candidate is administered through intravenous and subcutaneous routes. The drug candidate is an anti-CD40 monoclonal antibody. It was under development for the treatment of Grave's hyperthyroidism and rheumatoid arthritis. It was under development for the treatment of kidney transplant rejection and liver transplant rejection.
XOMA, formerly XOMA Ltd, is a biopharmaceutical company. It develops antibody-based therapeutics. Its lead product, Gevokizumab is a monoclonal antibody used for the treatment of a wide variety of inflammatory diseases and other diseases. Its other pipeline products include RZ358, XMetA, X213 (formerly LFA 102) and PTH1R. XOMA X358 is a human negative allosteric modulating insulin receptor antibody; X213 is an allosteric inhibitor of prolactin action. XOMA has a developed proprietary antibody platform, optimization and development technologies, comprising ADAPT, ModulX and OptimX. It operates through its subsidiaries in Bermuda, Ireland, and the US. XOMA is headquartered in Berkeley, California, the US.
The company reported revenues of (US Dollars) US$38.2 million for the fiscal year ended December 2021 (FY2021), an increase of 29.9% over FY2020. In FY2021, the company’s operating margin was 45.1%, compared to an operating margin of 42.3% in FY2020. In FY2021, the company recorded a net margin of 41.4%, compared to a net margin of 45.3% in FY2020. The company reported revenues of US$0.5 million for the third quarter ended September 2022, a decrease of 54.1% over the previous quarter.
Quick View – Iscalimab
|Highest Development Stage|